Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
Stock Score/grades
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
- Altman Z Score -1.97
- Piotroski Score 3.00
- Grade Buy
- Symbol (RGNX)
- Company REGENXBIO Inc.
- Price $9.59
- Changes Percentage (4.47%)
- Change $0.41
- Day Low $9.01
- Day High $9.82
- Year High $28.80
REGENXBIO Inc., a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's lead product candidate is RGX-314, which is in Phase III clinical trial for the treatment of wet age-related macular degeneration. It is also developing RGX-121 that is in Phase I/II clinical trial to treat mucopolysaccharidosis type II;RGX-111, which is in Phase I/II clinical trial for treating mucopolysaccharidosis type I;RGX-181 which is in pre clinic stage for the treatment of late-infantile neuronal ceroid lipofuscinosis type II disease;RGX-202, to treat Duchenne muscular dystrophy which is in phase I/II clinical trial; and RGX-381, to treat the ocular manifestations of CLN2 disease which is in preclinical stage. REGENXBIO Inc. also licenses its NAV Technology Platform to other biotechnology and pharmaceutical companies; and has a collaboration and license agreement with Neurimmune AG to develop novel gene therapies. REGENXBIO Inc. was founded in 2008 and is headquartered in Rockville, Maryland.
- Last Earnings
- Ex-Dividend for 5/16 Dividend
- Dividend Payable
- Today N/A
- Next Earnings (Estimated) 02/25/2025
- Fiscal Year End N/A
- Average Stock Price Target $36.50
- High Stock Price Target $40.00
- Low Stock Price Target $18.00
- Potential Upside/Downside N/A
- Consensus Rating Strong Sell
- Rating Score (0-4) N/A
- Research Coverage N/A
- EPS (Most Recent Fiscal Year) -$5.87
- Trailing P/E Ratio -2.4
- Forward P/E Ratio -2.4
- P/E Growth -2.4
- Net Income $-263,494,000
Income Statement
Quarterly
Annual
Latest News of RGNX
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
-
REGENXBIO Inc. (RGNX) Stock Price, News, Quote & History - Yahoo Finance
REGENXBIO Inc. is a US biotechnology company specializing in gene therapies using NAV Technology Platform to treat genetic defects. They have various product candidates in development for diseases lik...
By Yahoo! Finance | 3 months ago -
REGENXBIO Inc. (RGNX) Stock Price, News, Quote & History
REGENXBIO Inc. is a US-based biotechnology company specializing in gene therapies using its NAV Technology Platform. They have multiple gene therapy products in the pipeline, including treatments for ...
By Yahoo! Finance | 3 months ago -
Why Did Analysts Maintain a Bullish Stance on REGENXBIO Inc. (RGNX) Despite Decline In Its Revenue Growth?
A list of Top 10 Small-Cap Stocks with Highest Upside Potential includes REGENXBIO Inc. (NASDAQ: RGNX), a clinical-stage biotech firm focusing on gene therapy. Analysts predict a 226....
By Yahoo! Finance | 4 months ago
